ECSP055568A - Composición de comprimido de liberación sostenida de pramipexol - Google Patents

Composición de comprimido de liberación sostenida de pramipexol

Info

Publication number
ECSP055568A
ECSP055568A EC2005005568A ECSP055568A ECSP055568A EC SP055568 A ECSP055568 A EC SP055568A EC 2005005568 A EC2005005568 A EC 2005005568A EC SP055568 A ECSP055568 A EC SP055568A EC SP055568 A ECSP055568 A EC SP055568A
Authority
EC
Ecuador
Prior art keywords
sustained release
composition
pramipexol
release compressed
compressed
Prior art date
Application number
EC2005005568A
Other languages
English (en)
Inventor
Gregory E Amidon
Loksidh D Ganorkar
John M Heimlich
Ernest J Lee
Robert M Noack
Joseph P Reo
Connie J Skoug
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of ECSP055568A publication Critical patent/ECSP055568A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

La presente invención se refiere a formulaciones de comprimido, y más particularmente a una composición de comprimido de liberación sostenida para la administración oral de un fármaco o profármaco soluble en agua, ejemplificado por diclorhidrato de pramipexol.
EC2005005568A 2002-07-25 2005-01-24 Composición de comprimido de liberación sostenida de pramipexol ECSP055568A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39842702P 2002-07-25 2002-07-25
US39844702P 2002-07-25 2002-07-25
US47951303P 2003-06-18 2003-06-18

Publications (1)

Publication Number Publication Date
ECSP055568A true ECSP055568A (es) 2005-04-18

Family

ID=31192087

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005005568A ECSP055568A (es) 2002-07-25 2005-01-24 Composición de comprimido de liberación sostenida de pramipexol

Country Status (41)

Country Link
US (2) US20050226926A1 (es)
EP (2) EP1531814B1 (es)
JP (1) JP4700963B2 (es)
KR (1) KR100712832B1 (es)
CN (1) CN1313092C (es)
AP (1) AP2201A (es)
AR (1) AR040681A1 (es)
AT (1) ATE406162T1 (es)
AU (1) AU2003261241B2 (es)
BR (1) BR0312960A (es)
CA (1) CA2492854C (es)
CR (1) CR7661A (es)
CU (1) CU23440B7 (es)
CY (1) CY1110408T1 (es)
DE (1) DE60323235D1 (es)
DK (1) DK1531814T3 (es)
EA (2) EA200702187A1 (es)
EC (1) ECSP055568A (es)
ES (1) ES2310673T3 (es)
GE (1) GEP20074048B (es)
HK (1) HK10777456A1 (es)
HR (1) HRP20041235B1 (es)
IL (1) IL166078A0 (es)
IS (1) IS7623A (es)
MA (1) MA27328A1 (es)
ME (1) MEP52308A (es)
MX (1) MXPA05001054A (es)
MY (1) MY138846A (es)
NO (1) NO334298B1 (es)
NZ (1) NZ537790A (es)
OA (1) OA13303A (es)
PA (1) PA8578301A1 (es)
PE (1) PE20040130A1 (es)
PL (1) PL215587B1 (es)
PT (1) PT1531814E (es)
RS (1) RS51719B (es)
SI (1) SI1531814T1 (es)
TW (1) TWI347849B (es)
UY (1) UY27912A1 (es)
WO (1) WO2004010997A1 (es)
ZA (1) ZA200500439B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1453505E (pt) * 2001-12-11 2010-12-16 Univ Virginia Utilização de pramipexol para tratamento da esclerose lateral amiotrófica
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
MY136318A (en) * 2002-07-25 2008-09-30 Pharmacia Corp Sustained-release tablet composition
AR040682A1 (es) * 2002-07-25 2005-04-13 Pharmacia Corp Forma de dosificacion una vez al dia de pramipexol
US9101155B2 (en) 2003-07-11 2015-08-11 Asahi Kasei Chemicals Corporation Functional starch powder
BRPI0513847A (pt) 2004-08-13 2008-05-20 Boehringer Ingelheim Int formulação de comprimido de liberação extendida contendo pramipexol ou um sal farmaceuticamente aceitável do mesmo, método para a fabricação do mesmo e uso do mesmo
EP2431027A1 (en) 2004-08-13 2012-03-21 Boehringer Ingelheim International GmbH Extended release pellet formulation containing Pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
EP1803447B1 (en) * 2004-09-09 2009-07-22 Psicofarma, S.A. De C.V. Pharmaceutical composition for the sustained release of hydralazine and use thereof as a support for cancer treatment
EP1731514A1 (en) * 2005-06-02 2006-12-13 Sandoz AG Process for the preparation of Pramipexole
EP1917014B1 (en) * 2005-08-15 2009-10-07 University Of Virginia Patent Foundation Neurorestoration with r(+) pramipexole
WO2007090883A1 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Extended release formulation
WO2007090882A2 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Pharmaceutical extended release compositions comprising pramipexole
US20090041844A1 (en) * 2006-02-10 2009-02-12 Boehringer Ingelheim International Gmbh Modified Release Formulation
US8518926B2 (en) 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
US20070259930A1 (en) * 2006-04-10 2007-11-08 Knopp Neurosciences, Inc. Compositions and methods of using r(+) pramipexole
WO2007137071A2 (en) 2006-05-16 2007-11-29 Knopp Neurosciences, Inc. Compositions of r(+) and s(-) pramipexole and methods of using the same
WO2008001204A2 (en) * 2006-06-29 2008-01-03 Antares Pharma Ipl Ag Transdermal compositions of pramipexole having enhanced permeation properties
US8524695B2 (en) * 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
CN101715443A (zh) 2007-03-14 2010-05-26 诺普神经科学股份有限公司 手性纯化的取代的苯并噻唑二胺的合成
JP2010525018A (ja) * 2007-04-24 2010-07-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング プラミペキソール又はその医薬的に許容できる塩を含有する徐放性錠剤型製剤との組成物
US20080299189A1 (en) * 2007-06-04 2008-12-04 Drugtech Corporation Controlled release dopamine agonist compositions
US20090304794A1 (en) * 2008-06-09 2009-12-10 Supernus Pharmaceuticals, Inc. Controlled release formulations of pramipexole
US20110190356A1 (en) 2008-08-19 2011-08-04 Knopp Neurosciences Inc. Compositions and Methods of Using (R)- Pramipexole
JP2012530723A (ja) * 2009-06-19 2012-12-06 ノップ ニューロサイエンシーズ、インク． 筋萎縮性側索硬化症を治療するための組成物及び方法
EP2448411A4 (en) * 2009-07-02 2012-11-28 Supernus Pharmaceuticals Inc METHOD OF TREATING A NEUROLOGICAL DISORDER
WO2011037976A2 (en) * 2009-09-22 2011-03-31 Dr. Reddy's Laboratories Limited Pramipexole pharmaceutical formulations
EP2525786A2 (en) 2010-01-18 2012-11-28 Synthon BV Pramipexole extended release tablets
TR201001862A1 (tr) 2010-03-11 2011-10-21 Sanovel �La� San.Ve T�C.A.�. Kontrollü salım gerçekleştiren pramipeksol formülasyonları.
EP2575780A1 (en) 2010-05-24 2013-04-10 Lupin Limited Extended release formulation of pramipexole
KR101307334B1 (ko) 2010-07-02 2013-09-12 주식회사 바이오파마티스 프라미펙솔 또는 이의 약학적으로 허용되는 염을 포함하는 안정성이 개선된 서방형 약학 조성물
WO2013034173A1 (en) 2011-09-06 2013-03-14 Synthon Bv Pramipexole extended release tablets
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
EP2732812A1 (de) 2012-11-15 2014-05-21 Aristo Pharma GmbH Pramipexol-Retardtablettenformulierung
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
US10828284B2 (en) 2013-07-12 2020-11-10 Knopp Biosciences Llc Compositions and methods for treating conditions related to elevated levels of eosinophils and/or basophils
AU2014306597B2 (en) 2013-08-13 2018-05-17 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
CA2921378A1 (en) 2013-08-13 2015-02-19 Knopp Biosciences Llc Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders
CN103520128B (zh) 2013-10-12 2018-08-21 石家庄杏林锐步医药科技股份有限公司 一种普拉克索的缓释片剂、制备方法及其用途
EA201992414A1 (ru) 2017-04-10 2020-03-16 Чейс Терапьютикс Корпорейшн Комбинация nk1-антагониста и способ лечения синуклеинопатий
MA49524A (fr) 2017-06-30 2021-05-26 Chase Therapeutics Corp Compositions d'antagoniste de nk-1 et méthodes destinées à être utilisées dans le traitement de la dépression
CN109316466B (zh) * 2017-07-31 2022-04-05 深圳翰宇药业股份有限公司 一种盐酸普拉克索缓释制剂及其制备方法
CA3072994A1 (en) 2017-08-17 2019-02-21 Zi-Qiang Gu Pamoate salt of monoamine anti-parkinson's agents, method of preparation and use thereof
CN113876729B (zh) * 2021-11-11 2023-05-30 南通联亚药业股份有限公司 一种盐酸普拉克索缓释片剂及其制备方法

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US15735A (en) * 1856-09-16 Improvement in harvesters
US2887440A (en) * 1957-08-12 1959-05-19 Dow Chemical Co Enteric coating
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
JPS58403B2 (ja) 1975-07-24 1983-01-06 武田薬品工業株式会社 Ｌ− アスコルビンサンセイザイノ セイゾウホウ
US4140755A (en) 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
CH649215A5 (de) 1981-04-29 1985-05-15 Hoffmann La Roche Pharmazeutische praeparate.
SE8103843L (sv) 1981-06-18 1982-12-19 Astra Laekemedel Ab Farmaceutisk mixtur
US4424235A (en) 1981-09-14 1984-01-03 Hoffmann-La Roche Inc. Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor
ATE45735T1 (de) 1984-12-22 1989-09-15 Thomae Gmbh Dr K Tetrahydro-benzthiazole, deren herstellung und deren verwendung als zwischenprodukte oder als arnzneimittel.
DE3447075A1 (de) * 1984-12-22 1986-07-03 Dr. Karl Thomae Gmbh, 7950 Biberach Tetrahydro-benzthiazole, deren herstellung und deren verwendung als zwischenprodukte oder als arzneimittel
US4738851A (en) 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US4709712A (en) 1986-10-22 1987-12-01 Dermatalogical Products Of Texas Polycarboxylic acid polymer gels as protective agents
GB8828020D0 (en) 1988-12-01 1989-01-05 Unilever Plc Topical composition
US5026559A (en) 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
KR0167346B1 (ko) 1989-06-09 1999-01-15 로버트 에이. 아미테이지 중추신경계 활성을 갖는 헤테로사이클릭 아민
US5273975A (en) 1989-06-09 1993-12-28 The Upjohn Company Heterocyclic amines having central nervous system activity
GB9015822D0 (en) 1990-07-18 1990-09-05 Beecham Group Plc Compositions
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5656296A (en) * 1992-04-29 1997-08-12 Warner-Lambert Company Dual control sustained release drug delivery systems and methods for preparing same
US5431920A (en) 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
US5458887A (en) * 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
WO1997004752A1 (en) * 1995-07-26 1997-02-13 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions of conjugated estrogens and methods for their use
CA2290624C (en) 1997-06-06 2006-12-05 John W. Shell Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
EP0999830A1 (en) 1997-07-01 2000-05-17 Pfizer Inc. Sertraline salts and sustained-release dosage forms of sertraline
US5895663A (en) 1997-07-31 1999-04-20 L. Perrigo Company Pseudoephedrine hydrochloride extended-release tablets
CA2211778A1 (en) * 1997-08-14 1999-02-14 Francois Carriere Preparation of pregelatinized high amylose starch and debranched starch useful as an excipient for controlled release of active agents
US7153845B2 (en) 1998-08-25 2006-12-26 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
DE69819748T2 (de) 1997-09-12 2004-09-30 Columbia Laboratories (Bermuda) Ltd. Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen
US6624200B2 (en) 1998-08-25 2003-09-23 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US6248358B1 (en) 1998-08-25 2001-06-19 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets and methods of making and using the same
US6197339B1 (en) * 1997-09-30 2001-03-06 Pharmacia & Upjohn Company Sustained release tablet formulation to treat Parkinson's disease
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
GB9802201D0 (en) * 1998-02-03 1998-04-01 Cerestar Holding Bv Free-flowable directly compressible starch as binder,disintegrant and filler for compresion tablets and hard gelatine capsules
CA2323177A1 (en) * 1998-03-11 1999-09-16 Susan Marie Milosovich Composition
GB9812426D0 (en) 1998-06-10 1998-08-05 Reckitt & Colmann Prod Ltd Improvements in or relating to organic compositions
TW407058B (en) 1998-07-17 2000-10-01 Dev Center Biotechnology Oral cisapride dosage forms with an extended duration
DE19906290A1 (de) 1999-02-15 2000-08-17 Falk Pharma Gmbh Arzneimittel zur Behandlung bzw. Prävention von Darmkrebs
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
KR100660594B1 (ko) 1999-03-31 2006-12-22 얀센 파마슈티카 엔.브이. 방출 조절형 제제중의 프리젤라틴화 전분
DE19927688A1 (de) * 1999-06-17 2000-12-21 Gruenenthal Gmbh Mehrschichttablette zur Verabreichung einer fixen Kombination von Tramadol und Diclofenac
CN1660108A (zh) 1999-07-01 2005-08-31 法玛西雅厄普约翰美国公司 高度选择性去甲肾上腺素再摄取抑制剂及其用途
AP2002002410A0 (en) 1999-08-04 2002-03-31 Ranbaxy Laboratories Ltd Hydrodynamically Balancing Oral Drug Delivery System
US6387403B1 (en) 1999-09-15 2002-05-14 Alza Corporation Dosage forms and methods for providing effective reboxetine therapy with once-a-day dosing
CA2384840A1 (en) 1999-09-30 2001-04-05 The General Hospital Corporation Use of pramipexole as a treatment for ***e craving
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
CA2394222A1 (en) * 1999-12-22 2001-06-28 Pharmacia Corporation Sustained-release formulation of a cyclooxygenase-2 inhibitor
US6467637B2 (en) 2000-01-27 2002-10-22 The York Group, Inc. Death care merchandising system
WO2001062236A2 (en) 2000-02-24 2001-08-30 Pharmacia & Upjohn Company New drug combinations comprising a norepinephrine reuptake inhibitor and an antimuscarinic agent
US6277875B1 (en) * 2000-07-17 2001-08-21 Andrew J. Holman Use of dopamine D2/D3 receptor agonists to treat fibromyalgia
ES2187249B1 (es) 2000-09-18 2004-09-16 Synthon Bv Procedimiento para la preparacion de 2-amino-6-(alquil)amino-4,5,6,7-tetrahidrobenzotiazoles.
SE0004671D0 (sv) 2000-12-15 2000-12-15 Amarin Dev Ab Pharmaceutical formulation
DE10138275A1 (de) 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Verbindungen zur Beseitigung der Anhedonie
AU2002358270A1 (en) 2001-12-20 2003-07-09 Pharmacia Corporation Zero-order sustained released dosage forms and method of making the same
AR040682A1 (es) 2002-07-25 2005-04-13 Pharmacia Corp Forma de dosificacion una vez al dia de pramipexol
BR0312876A (pt) 2002-07-25 2005-06-28 Pharmacia Corp Método de preparação de formas de dosagem sólidas revestidas em duas camadas compreendendo um polìmero insolúvel em água e um agente formador de poros solúvel em água
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
MY136318A (en) 2002-07-25 2008-09-30 Pharmacia Corp Sustained-release tablet composition
US20040132826A1 (en) 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
AU2003224467A1 (en) 2003-03-11 2004-09-30 Korea United Pharm, Inc. Process for the preparing of hardcapsule formulation containing lansoprazole
CA2520321A1 (en) 2003-04-04 2004-10-14 Pharmacia Corporation Oral extended release compressed tablets of multiparticulates
US20050020589A1 (en) 2003-06-18 2005-01-27 Pfizer Inc. Sustained-release tablet composition comprising a dopamine receptor agonist
BRPI0513847A (pt) 2004-08-13 2008-05-20 Boehringer Ingelheim Int formulação de comprimido de liberação extendida contendo pramipexol ou um sal farmaceuticamente aceitável do mesmo, método para a fabricação do mesmo e uso do mesmo
EP2431027A1 (en) 2004-08-13 2012-03-21 Boehringer Ingelheim International GmbH Extended release pellet formulation containing Pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
WO2006046256A1 (en) 2004-10-27 2006-05-04 Alembic Limited Extended release formulation of pramipexole dihydrochloride
CA2613631A1 (en) 2005-06-23 2007-01-04 Spherics, Inc. Improved dosage forms for movement disorder treatment
CA2613107A1 (en) 2005-06-23 2007-01-04 Spherics, Inc. Delayed release or extended-delayed release dosage forms of pramipexole
EP1917014B1 (en) 2005-08-15 2009-10-07 University Of Virginia Patent Foundation Neurorestoration with r(+) pramipexole
WO2007054976A2 (en) 2005-11-08 2007-05-18 Panacea Biotec Ltd. Lipid based controlled release pharmaceutical composition
WO2007090883A1 (en) 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Extended release formulation
US20090041844A1 (en) 2006-02-10 2009-02-12 Boehringer Ingelheim International Gmbh Modified Release Formulation
WO2007090882A2 (en) 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Pharmaceutical extended release compositions comprising pramipexole
EP1886665A1 (en) 2006-08-01 2008-02-13 Boehringer Ingelheim Pharma GmbH & Co. KG Gastro retentive delivery system

Also Published As

Publication number Publication date
EA009663B1 (ru) 2008-02-28
BR0312960A (pt) 2005-06-14
IL166078A0 (en) 2006-01-15
TW200418523A (en) 2004-10-01
EP1987832A1 (en) 2008-11-05
KR20050062516A (ko) 2005-06-23
AU2003261241B2 (en) 2009-06-18
CU23440B7 (es) 2009-10-16
GEP20074048B (en) 2007-02-26
EA200702187A1 (ru) 2008-06-30
HK10777456A1 (en) 2007-11-30
HRP20041235A2 (en) 2005-06-30
RS51719B (sr) 2011-10-31
IS7623A (is) 2004-12-29
PE20040130A1 (es) 2004-03-06
JP4700963B2 (ja) 2011-06-15
MY138846A (en) 2009-07-31
CA2492854A1 (en) 2004-02-05
PL375696A1 (en) 2005-12-12
UY27912A1 (es) 2004-02-27
MEP52308A (en) 2011-02-10
NZ537790A (en) 2005-10-28
WO2004010997A8 (en) 2005-02-24
AU2003261241A1 (en) 2004-02-16
WO2004010997A1 (en) 2004-02-05
CR7661A (es) 2005-06-08
EP1531814A1 (en) 2005-05-25
PT1531814E (pt) 2008-10-29
CN1671382A (zh) 2005-09-21
MXPA05001054A (es) 2005-04-08
DE60323235D1 (de) 2008-10-09
MA27328A1 (fr) 2005-05-02
ATE406162T1 (de) 2008-09-15
HRP20041235B1 (hr) 2013-07-31
US20100316710A1 (en) 2010-12-16
AP2005003205A0 (en) 2005-03-31
KR100712832B1 (ko) 2007-04-30
JP2005538106A (ja) 2005-12-15
ZA200500439B (en) 2006-08-30
ES2310673T3 (es) 2009-01-16
NO20050093L (no) 2005-02-24
EP1531814B1 (en) 2008-08-27
AR040681A1 (es) 2005-04-13
US8399016B2 (en) 2013-03-19
NO334298B1 (no) 2014-01-27
CY1110408T1 (el) 2015-04-29
PL215587B1 (pl) 2013-12-31
RS20050059A (en) 2007-08-03
OA13303A (en) 2007-04-13
SI1531814T1 (sl) 2008-12-31
CA2492854C (en) 2009-10-20
US20050226926A1 (en) 2005-10-13
CN1313092C (zh) 2007-05-02
PA8578301A1 (es) 2004-07-20
DK1531814T3 (da) 2008-10-13
AP2201A (en) 2011-01-24
EA200500079A1 (ru) 2005-06-30
TWI347849B (en) 2011-09-01

Similar Documents

Publication Publication Date Title
ECSP055568A (es) Composición de comprimido de liberación sostenida de pramipexol
CY1120138T1 (el) Στερεη φαρμακευτικη μορφη δοσολογιας που περιλαμβανει μια στερεη διασπορα αναστολεα πρωτεασης toy hiv
ECSP055569A (es) Forma de dosificación de pramipexol en una dosis única diaria
BR0306870A (pt) Composição farmacêutica oral, e, método para preparar a mesma
AR065809A1 (es) Formulaciones farmaceuticas que contienen un inhibidor sglt2
RS77904A (en) Oral administration form for difficulty soluble basic active ingredients which are applied orally
ECSP077243A (es) Formulación de pelet de liberación extendida que contiene pramipexol o una de sus sales farmacéuticamente aceptable, un método para su fabricación y su uso
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
TW200736223A (en) N-(pyridin-2-yl)-sulfonamide derivatives
ITMI20011337A0 (it) Composizioni farmaceutiche orali a rilascio modificato del principio attivo
NO20080827L (no) Faste doseringsformuleringer av narkotiske legemidler som har forbedret bukal adsorpsjon
NO20082988L (no) Vedvarende frigivningsformulering innbefattende oktreotid og to eller flere polylaktid-ko-glykolidpolymerer
CY1110906T1 (el) Φαρμακευτικη συνθεση για ρινικη χορηγηση φεντανυλης
RS54244B1 (en) NALBUFINE BASED FORMULATIONS AND THEIR USE
TNSN06220A1 (en) Benzimidazole derivatives
TNSN07337A1 (en) Pharmaceutical composition comprising an indolylmaleimide derivative
BRPI0415053B8 (pt) inibidor de glicoproteína-p, método para preparar o mesmo e composição farmacêutica que compreende o mesmo
BRPI0412458A (pt) composições farmacêuticas oralmente dosadas compreendendo um agente de liberação na forma micronizada
ITMI20011338A0 (it) Composizioni farmaceutiche orali a rilascio immediato del principio attivo
NO20083183L (no) Fast farmasoytisk sammensetning inneholdende irbesartan
CR8172A (es) Saquinavir mesilato en forma de dosificacion farmaceutica oral
EA200600953A1 (ru) Дозированные формы торсемида пролонгированного высвобождения
TR200301553A1 (tr) İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar
MY141008A (en) Oral formulations of deoxypeganine and their uses
ATE357220T1 (de) Pharmazeutische zusammensetzung mit modifizierter freisetzung